• Alnylam Pharmaceuticals will present five-year HELIOS-B results for Amvuttra in ATTR cardiomyopathy at AHA Scientific Sessions, Nov. 6-9, 2026.
• An additional HELIOS-B analysis will show Amvuttra preserved exercise capacity and cardiopulmonary performance over two years compared with placebo.
• At ISA, Nov. 15-18, a HELIOS-B analysis will show improved neuropathy-related quality of life versus placebo in patients with ATTR cardiomyopathy.
• Real-world data will show greater heart failure prevalence and comorbidity burden among second-line Amvuttra patients, supporting earlier treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261103351345) on November 03, 2026, and is solely responsible for the information contained therein.